CD161⁺ Treg as a potential biomarker for evaluating disease activity and treatment efficacy in rheumatoid arthritis - PubMed
3 hours ago
- #Biomarker
- #Rheumatoid Arthritis
- #Tregs
- CD161+ Tregs are significantly elevated in rheumatoid arthritis (RA) patients compared to healthy controls.
- Higher CD161+ Treg levels correlate with disease activity scores (DAS28-ESR) and key serological markers like RF, IgA, and IgM.
- CD161+ Tregs show positive correlations with pro-inflammatory cells (TNF-α+CD4+T cell, Th17) and negative correlations with naïve Th cells and effector T cells.
- CD161+ Treg levels decrease significantly following effective therapy, especially with csDMARDs combined with tocilizumab.
- CD161+ Tregs may serve as a biomarker for assessing RA disease activity and treatment efficacy.